FEB 09, 2017 9:00 AM PST

Improved decision making in the drug discovery process using an innovative approach to modelling chronic liver disease

Speaker
  • Director & Head of Future Therapeutics & Technologies, Abbvie
    Biography
      Steve is an experienced professional in the early stages of drug discovery and development -from target identification, through project initiation up to proof of concept. This has been gained at Pfizer, AstraZeneca and Abbott/AbbVie. Steve has broad-based scientific expertise, primarily in the neuroscience area and more recently in chronic liver disease and more generally in immunology and oncology. Throughout his career Steve has managed both large and small groups of scientists and established a number of successful external collaborations with both academics and small companies. Currently Steve has two major roles - Firstly, leading the Discovery effort focused on liver disease at AbbVie, aimed at identifying treatments for NASH/NAFLD and also autoimmune diseases of the liver. Secondly, Steve head Future Therapeutics & Technologies - a team tasked with the identification and 'internalisation' of atypical therapeutic modalities.

    Abstract

    DATE: February 9, 2017
    TIME: 9:00am PT, 12:00pm ET

    Traditional models of liver fibrosis in rodents involve many weeks of induction, with frequent injections of a pro-fibrotic agent. The most commonly used end-point in these studies is immuno-histochemical analysis of markers of fibrosis in the liver. This whole process is time-consuming, very labor-intensive in terms of animal handling, processing of the tissues and produces only a semi-quantitative measure of fibrosis. In addition, if pharmacological agents are to be explored, this means more ‘hands-on’ work for the experimentalist due to the likelihood of the need for daily dosing and adds substantially to the cost of the study because of the amounts of compound required. We have modelled the inflammatory component which drives liver fibrosis, by using the concanavalin A (conA) challenge to evoke an acute liver inflammation and the Vium ‘Digital Vivarium’ as a way of monitoring mouse behavior in response to the challenge. Acute liver inflammation evokes measurable changes in mouse behavior over the course of 24hrs and we believe these behavioral measures will be useful in testing the efficacy of pharmacological agents which suppress the inflammation.  By focusing on the inflammatory drivers of the pathology we dramatically reduce the duration of the studies, obtain a quantitative measure of the effect of the conA whilst minimizing handler intervention and reduce compound demand. Moreover, we believe the value of efficient in vivo testing of hypotheses enables us to embrace ‘systems biology’ in a way that is entirely compatible with aspects of the ‘3Rs’. Using a behavioral assessment of inflammation enables us to make rapid decisions on mechanisms and targets of interest. This reduces costs and time but maybe more importantly, promotes improved iterative decision-making regarding targets and compounds.


    Show Resources
    You May Also Like
    NOV 10, 2020 7:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    NOV 10, 2020 7:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    AUG 18, 2020 10:00 AM PDT
    C.E. CREDITS
    AUG 18, 2020 10:00 AM PDT
    DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
    Loading Comments...
    Show Resources
    Attendees
    • See more